UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance

Drug metabolism and disposition, 2004-11, Vol.32 (11), p.1247-1253

2004

Volltextzugriff (PDF)

Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump

Drug metabolism and disposition, 2014-04, Vol.42 (4), p.566-574

2014

Volltextzugriff (PDF)

The pivotal role of hepatocytes in drug discovery

Chemico-biological interactions, 2007-05, Vol.168 (1), p.2-15

2007

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

Journal of pharmaceutical sciences, 2015-09, Vol.104 (9), p.2813-2823

2015

Volltextzugriff (PDF)

Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo

Drug metabolism and disposition, 2007-06, Vol.35 (6), p.859-865

2007

Volltextzugriff (PDF)

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins

Drug metabolism and disposition, 2014-08, Vol.42 (8), p.1301-1313

2014

Volltextzugriff (PDF)

The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery

Drug metabolism and disposition, 2012-08, Vol.40 (8), p.1641-1648

2012

Volltextzugriff (PDF)

The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases

Drug metabolism and disposition, 2003-06, Vol.31 (6), p.762-767

2003

Volltextzugriff (PDF)

An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes

Drug metabolism and disposition, 2004-01, Vol.32 (1), p.140-148

2004

Volltextzugriff (PDF)

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis

Journal of medicinal chemistry, 2022-07, Vol.65 (13), p.8948-8960

2022

Volltextzugriff (PDF)

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Journal of medicinal chemistry, 2021-11, Vol.64 (21), p.15549-15581

2021

Volltextzugriff (PDF)

The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement

European journal of nuclear medicine and molecular imaging, 2024-03, Vol.51 (4), p.978-990

2024

Volltextzugriff (PDF)

Late Intervention with a Myeloperoxidase Inhibitor Stops Progression of Experimental Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2012, Vol.185 (1), p.34-43

2012

Volltextzugriff (PDF)

Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer

Molecular imaging and biology, 2024-04, Vol.26 (2), p.301-309

2024

Volltextzugriff (PDF)

Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney

Drug metabolism and disposition, 2001-02, Vol.29 (2), p.121

2001

Volltextzugriff (PDF)

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.831-856

2019

Volltextzugriff (PDF)

Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis

ACS medicinal chemistry letters, 2021-09, Vol.12 (9), p.1413-1420

2021

Volltextzugriff (PDF)

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology

British journal of clinical pharmacology, 2003-02, Vol.55 (2), p.175-181

2003

Volltextzugriff (PDF)

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain

Journal of medicinal chemistry, 2017-03, Vol.60 (6), p.2513-2525

2017

Volltextzugriff (PDF)

Development of a high-throughput mass spectrometry based analytical method to support an in vitro OATP1B1 inhibition screening assay

Rapid communications in mass spectrometry, 2016-08, Vol.30 (15), p.1787-1796

2016

Volltextzugriff (PDF)

Correction to Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na V 1.7 Inhibitors for the Treatment of Pain

Journal of medicinal chemistry, 2019-02, Vol.62 (4), p.2213-2213

2019

Volltextzugriff (PDF)

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na V 1.7 Inhibitors for the Treatment of Pain

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.831-856

2019

Volltextzugriff (PDF)

Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation

Bioorganic & medicinal chemistry, 2017-10, Vol.25 (20), p.5490-5505

2017

Volltextzugriff (PDF)

Discovery, Synthesis, and Preclinical Characterization of N‑(3-Chloro-4-fluorophenyl)‑1H‑pyrazolo[4,3‑b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)

ACS chemical neuroscience, 2016-09, Vol.7 (9), p.1192-1200

2016

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance

Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump

The pivotal role of hepatocytes in drug discovery

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins

The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery

The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases

An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement

Late Intervention with a Myeloperoxidase Inhibitor Stops Progression of Experimental Chronic Obstructive Pulmonary Disease

Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer

Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain

Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain

Development of a high-throughput mass spectrometry based analytical method to support an in vitro OATP1B1 inhibition screening assay

Correction to Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na V 1.7 Inhibitors for the Treatment of Pain

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na V 1.7 Inhibitors for the Treatment of Pain

Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation

Discovery, Synthesis, and Preclinical Characterization of N‑(3-Chloro-4-fluorophenyl)‑1H‑pyrazolo[4,3‑b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)

Suchergebnisse filtern